API | etaracizumab

etaracizumab (abegrin) Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer. It is manufactured by MedImmune. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
etaracizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Integrin alpha-V (Homo sapiens) ^UniProt
- Integrin beta-3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Arthritis, Rheumatoid (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Intestinal Neoplasms (Phase 1)

Lymphoma (Phase 1)

Melanoma (Phase 2)

Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue